Skip to main content

Advertisement

SpringerLink
Log in

The antiviral prophylaxis of post-transplant lymphoproliferative disorder

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hanto DW, Gajl-Peczalska J, Frizzera G, et al (1983) Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg. 198: 356

    PubMed  Google Scholar 

  2. Hanto DWM, Sakamoto KM, Purtilo DTM, Simmons RLM, Najarian JSM (1981) The Epstein-Barr virus in the pathogenesis of posttransplant lymph oproliferative disorders. Surgery 90: 204

    PubMed  Google Scholar 

  3. Morgan G, Superina RA (1994) Lymphoproliferative disease after pediatric liver transplantation. J Pediatr Surg 29: 1192

    PubMed  Google Scholar 

  4. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA (1993) Post-Transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 56: 88

    PubMed  Google Scholar 

  5. Alfrey EJ, Friedman AL, Grossman RA, et al (1992) A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation 54: 250

    PubMed  Google Scholar 

  6. Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342: 1514

    PubMed  Google Scholar 

  7. Chen JMB, Barr ML, Chadburn A, et al (1993) Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 56: 527

    PubMed  Google Scholar 

  8. Aris RM, Maia DM, Neuringer IP, et al (1996) Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-native lung transplant recipient. Am J Respir Crit Care Med 154: 1712

    PubMed  Google Scholar 

  9. Nalesnik MA, Makowka L, Starzl TE (1988) The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 25: 367

    PubMed  Google Scholar 

  10. Nalesnik MA, Demetris AJ, Fung JJ, Starzl TE (1991) Lymphoproliferative disorders arising under immunosuppression with FK506: initial observations in a large transplant population. Transplant Proc 23: 1108

    PubMed  Google Scholar 

  11. Nalesnik MAM, Jaffe R, Starzl TE, et al (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133: 173

    PubMed  Google Scholar 

  12. Sheil AGR, Flavel S, Disney APS, Mathew TH, Hall BM (1987) Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transplant Proc 19: 2214

    PubMed  Google Scholar 

  13. Starzl T, Porter K, Iwatsuki S, et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet: 583

  14. Leblond V, Sutton L, Dorent R, et al (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 13: 961

    PubMed  Google Scholar 

  15. Preiksaitis JD, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DLJ (1992) Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 166:986

    PubMed  Google Scholar 

  16. Wilkinson AH, Smith JL, Hunsicker LG, et al (1989) Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 47: 293

    PubMed  Google Scholar 

  17. Davis CL, Harrison KL, McVicar JP, Forg PJ, Brunner MP, Marsh CL (1995) Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 9: 53

    PubMed  Google Scholar 

  18. Stratta RJ, Taylor RJ, Bynon JS, et al (1994) Viral prophylaxis in combined pancreas-kidney transplant recipients. Transplantation 57: 506

    PubMed  Google Scholar 

  19. Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV (1995) Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 20:514

    PubMed  Google Scholar 

  20. Keay S, Oldach D, Wiland A, et al (1998) Post-transplant lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 26: 596–600

    PubMed  Google Scholar 

  21. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323:1723

    PubMed  Google Scholar 

  22. Armitage JM, Komros RL, Stuart RS, et al (1991) Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 10: 877

    PubMed  Google Scholar 

  23. Wood BL, Sabath D, Broudy VC, Raghu G (1996) The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. Cancer 78: 2223

    PubMed  Google Scholar 

  24. Kocoshis SA (1994) Small bowel transplantation in infants and children. Pediatric Gastroenterol 23: 727

    Google Scholar 

  25. Todo S, Tzakis A, Abu-Elmagd K, et al (1995) Abdominal multivisceral transplantation. Transplantation 59:234

    PubMed  Google Scholar 

  26. Deeg HJ, Sanders J, Martin P, et al (1984) Secondary malignancies after marrow transplantation. Exp Hematol 12:660

    PubMed  Google Scholar 

  27. Zutter MM, Martin PJ, Sale GE, et al (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72: 520

    Google Scholar 

  28. Davey DD, Kamat D, Laszewski M, et al (1989) Epstein-Barr virus-related lymphoproliferative disorders following bone marrow transplantation: an immunologic and genotypic analysis. Mod Pathol 2: 27

    PubMed  Google Scholar 

  29. Montone KT, Friedman H, Hodinka RL, Hicks DG, Kant JA, Tomaszewski JE (1992) In situ hybridization for Epstein-Barr virus, Notl repeats in posttransplant lymphoproliferative disorder. Mod Pathol 5:292

    PubMed  Google Scholar 

  30. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86: 3333

    PubMed  Google Scholar 

  31. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA (1994) Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 97: 14

    Google Scholar 

  32. Shapiro RS, McClain K, Frizzera G, et al (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234

    PubMed  Google Scholar 

  33. Cohen JIM (1991) Epstein-Ban virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 70:137

    PubMed  Google Scholar 

  34. Gamier JL, Berger F, Betuel H, et al (1989) Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation. Nephrol Dial Transplant 4: 818

    PubMed  Google Scholar 

  35. Ho M, Miller G, Atchison RW, et al (1985) Epstein-Ban virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 152: 876

    PubMed  Google Scholar 

  36. Renard TH, Andrews WS, Foster ME (1991) Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 23:1473

    PubMed  Google Scholar 

  37. Purtilo DT (1980) Epstein-Barr virus-induced oncogenesis in immune-deficient individuals. Lancet I 8163:300–303

    Google Scholar 

  38. Walker RC, Marshall WE, Strickler JG, et al (1995) Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infec Dis 20:1346

    Google Scholar 

  39. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al (1995) An increased incidence of EpsteinBarr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59: 524

    PubMed  Google Scholar 

  40. Randhawa PS, Markin RS, Starzl TE, Demetris AJ (1990) Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Am J Surg Pathol 14:538

    PubMed  Google Scholar 

  41. Basgoz NM, Preiksaitis JKM (1995) Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 9:901

    PubMed  Google Scholar 

  42. Gamier J-L, Touraine J-L (1992) Syndromes lymphoproliferatifs associes au virus d'Epstein-Barr en transplantation. La Presse Med 21: 1994

    Google Scholar 

  43. Eklund B, Willebrand E von, Hockerstedt K, et al (1986) Lymphoproliferative disease after renal transplantation. Transplant Proc 18: 95

    Google Scholar 

  44. Penn I (1987) Cancers following cyclosporine therapy. Transplant Proc 19: 2211

    PubMed  Google Scholar 

  45. Penn I (1991) The changing pattern of posttransplant malignancies. Transplant Proc 23: 1101

    PubMed  Google Scholar 

  46. Crawford DH, Edwards JMB, Sweny P, Janossy G, Hoffbrand AV (1981) Long-term T-cell-mediated immunity to Epstein-Barn virus in renal-allograft recipients receiving cyclosporin A. Lancet I 8210: 10–12

    Google Scholar 

  47. Schooley RT, Arbit DI, Henle W, Hirsch MS (1984) T-Lymphocyte subset interactions in the cell-mediated immune response to Epstein-Ban virus. Cell Immunol 86:402

    PubMed  Google Scholar 

  48. Cockfield SM, Preiksaitis J, Harvey E, et al (1991) Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 23:1106

    PubMed  Google Scholar 

  49. Newell KA, Alonso EM, Whitington PF, et al (1996) Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 62: 370

    PubMed  Google Scholar 

  50. Ren EC, Chan SH (1988) Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation 45: 988

    PubMed  Google Scholar 

  51. Tsoukas CD, Carson DA, Fong S, Vaughan JH (1982) Molecular interactions in human T cell-mediated cytotoxicity to EBV J Immunol 129:1421

    PubMed  Google Scholar 

  52. Ellis D, Shapiro R, Jordan ML, et al (1994) Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 8:193

    PubMed  Google Scholar 

  53. Rosenthal IT, Wilkinson AH, Canfield CW et al (1991) Fulminant Epstein-Barr virus associated posttransplant lymphoproliferative disorders following OKT3 therapy. In: Abstracts of ASTP 10th Annual Meeting, 1991. Scientific Session and Business Meeting Chicago, abst. no. 129

  54. Bayliss GJ, Wolf H (1981) The spontaneous and induced synthesis of Epstein-Barr virus antigens in Raji cells immobilized on surfaces coated with anti-lymphocyte globulin. J Gen Virol 54: 397

    PubMed  Google Scholar 

  55. Bonnefoy-Berard N, Genestier L, Flacher M, et al (1994) Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 83:1051

    PubMed  Google Scholar 

  56. Bonnefoy-Berard N, Revillard J-P (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15:435

    PubMed  Google Scholar 

  57. Purtilo DT, Sakamoto K, Saemundsen AK, et al (1981) Documentation of Epstein-Ban virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by clinical, virological, and immunopathological studes. Cancer Res 41:4226

    PubMed  Google Scholar 

  58. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL (1985) Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39:461

    PubMed  Google Scholar 

  59. Patton DF, Wilkowski CW, Hanson CA, et al (1990) Epstein-Barr virus-determined clonality in posttransplant lymphoproliferative disease. Transplantation 49:1080

    PubMed  Google Scholar 

  60. Katz BZ, Saini U (1992) Presence of the diffuse early antigen of Epstein-Barr virus in lymphomas and lymphoproliferative disorders. Am J Pathol 140: 1247

    PubMed  Google Scholar 

  61. Mackett M, Cox C, Pepper SD, et al (1996) Immunisation of common marmosets with vaccinia virus expressing epstein-barr virus (EBV) gp340 and challenge with EBV J Med Virol 50: 263

    PubMed  Google Scholar 

  62. Katz BZ, Raab-Traub N, Miller G (1989) Latent and replicating forms of epstein-barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis 160:589

    PubMed  Google Scholar 

  63. Purtilo DT, Strobach RS, Okano M, Davis JR (1992) Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest 67: 5–23

    PubMed  Google Scholar 

  64. Ho M, Jaffe R, Miller G, et al (1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45: 719

    PubMed  Google Scholar 

  65. Thiru S, Calne RY, Nagington J (1981) Lymphoma in renal allograft patients treated with cyclosporin-A as one of the immunosuppressive agents. Transplant Proc 13: 359

    PubMed  Google Scholar 

  66. Thomas JA, Hotchin NA, Allday MJ, et al (1990) Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49:944

    PubMed  Google Scholar 

  67. Locker J, Nalesnik M (1989) Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 135: 977

    PubMed  Google Scholar 

  68. Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE (1996) Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol 9: 621

    PubMed  Google Scholar 

  69. Berg LC, MD, Major, USAF, Copenhaver CM, Morrison VA, et al (1992) B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in-situ hybridization. Hum Pathol 23:159

    PubMed  Google Scholar 

  70. Rocchi GM, De Felici AM, Ragona G, Heinz A (1977) Quantitative evaluation of Epstein-Barr-virusinfected mononuclear peripheral blood leukocytes in infectious mononucleosis. N Engl J Med 296: 132

    PubMed  Google Scholar 

  71. Wagner HJ, Bein G, Bitsch A, Kirchner H (1992) Detection and quantification of latently infected B lymphocytes in Epstein-Ban virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol 30:2826

    PubMed  Google Scholar 

  72. Rowe DT, Qu L, Reyes J, et al (1997) Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35:1612

    PubMed  Google Scholar 

  73. Birx DL, Redfield RR, Tosato G (1986) Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 314: 874

    PubMed  Google Scholar 

  74. Tosato G, Straus S, Henle W, Pike SE, Blaese RM (1985) Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol 134: 3082

    PubMed  Google Scholar 

  75. Riddler SA, Breinig MC, McKnight JLC (1994) Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84:972

    PubMed  Google Scholar 

  76. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C (1994) Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83: 2715

    PubMed  Google Scholar 

  77. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE (1995) Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 89:98

    PubMed  Google Scholar 

  78. Crompton CH, Cheung RK, Donjon C, et al (1994) Epstein-Barr virus surveillance after renal transplantation. Transplantation 57:1182

    PubMed  Google Scholar 

  79. Miller WE, Mosialos G, Kieff E, Raab-Traub N (1997) Epstein-Barr virus LMPt induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kB activation. J Virol 71:586

    PubMed  Google Scholar 

  80. Henderson S, Rowe M, Gregory C, et al (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65: 1107

    PubMed  Google Scholar 

  81. Straus S, Moderator, Cohen JI, MD, Tosato G, MD, Meier J, MD (1993) Epstein-Ban virus infections: biology, pathogenesis, and management. Ann Intern Med 118:45

    PubMed  Google Scholar 

  82. Robertson ES, Lin J, Kieff E (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 313, and 3C interact with RBPJk. J Virol 70: 3068

    PubMed  Google Scholar 

  83. Yalamanchili R, Harada S, Kieff E (1996) The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation. J Virol 70: 2468

    PubMed  Google Scholar 

  84. Devergne O, Hummel M, Koeppen H, et al (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70:1143

    PubMed  Google Scholar 

  85. Devergne O, Hatzivassiliou E, Izumi KM, et al (1996) Association of TRAFI, TRAF2, and TRAF3 with an Epstein-Barr virus LMPI domain important for B-lymphocyte transformation: role in NF-kB Activation. Mol Cell Biol 16:7098

    PubMed  Google Scholar 

  86. Wang D, Liebowitz D, Wang F, et al (1988) Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62:4173

    PubMed  Google Scholar 

  87. Tsujimoto Y (1989) Overexpression of the humanBCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA 86: 1958

    PubMed  Google Scholar 

  88. Murray PG, Swinnen LJ, Constandinou CM, et al (1996) BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 87:706

    PubMed  Google Scholar 

  89. Young L, Alfieri C, Hennessy K, et al (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080

    PubMed  Google Scholar 

  90. Peng M, Lundgren E (1992) Transient expression of the Epstein-Barr virus LMPI gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7:1775

    PubMed  Google Scholar 

  91. Crawford H, Edwards JMB, Sweny P, Hoffbrand AV, Janossy G (1981) Studies on long-term T-cell-mediated immunity to Epstein-Barr virus in immunosuppressed renal allograft recipients. Int J Cancer 28: 705

    PubMed  Google Scholar 

  92. Hubschier SG, Williams A, Davison SM, Young LS, Niedobitek G (1994) Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: an in situ hybridization study. Hepatology 20: 899

    PubMed  Google Scholar 

  93. Randhawa PS, Jaffe R, Demetris AJ, et al (1992) Expression of Epstein-Barr virus-encoded small Rna (by the eber-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 327: 1710

    PubMed  Google Scholar 

  94. Telenti A, Smith TF, Ludwig J, Keating MR, Krom RAF, Wiesner RH (1991) Epstein-Barr virus and persistent graft dysfunction after liver transplantation. Hepatology 14: 282

    PubMed  Google Scholar 

  95. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, O'Reilly R (1995) Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 15: 591

    PubMed  Google Scholar 

  96. Rooney CM, Smith CA, Ng CY, et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9

    PubMed  Google Scholar 

  97. Gilbert MJ, Riddell SR, Greenberg PD (1996) Developments in the diagnosis, prevention and therapy of viral infections after bone marrow transplantation: a focus on adoptive cellular immunotherapy. Curr Opin Infect Dis :234

  98. Riddell SR, Walter BA, Gilbert MJ, Greenberg PD (1994) Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 14 [Suppl 4]: S78

    PubMed  Google Scholar 

  99. Purtilo DT, Falk K, Pirruccello SJ, et al (1991) SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. Int J Cancer 47:510

    PubMed  Google Scholar 

  100. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB (1991) Epstein-Barr virus (EBV )associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173:147

    PubMed  Google Scholar 

  101. Boyle TJB, Tamburini M, Berend KR, Kizilbash AM, Borowitz MJ, Lyerly HKM (1992) Human B -cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. Surgery 112: 378

    PubMed  Google Scholar 

  102. Young L, Finerty S, Brooks L, Scullion F, Rickinson A, Morgan A (1989) Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol 63:1967

    PubMed  Google Scholar 

  103. Blanc-Brunat N, Laurin D, Vivier G, Touraine JL, Sergeant A, Gamier JL (1995) Epstein-Barr virus lymphoblastoid cell lines from transplanted patients induce B lymphomas in SCID/hu mice: study of EBV replication. Transplant Proc 27: 1776

    PubMed  Google Scholar 

  104. Miller G, Shope T, Coupe D, et al (1977) Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med 145: 948

    PubMed  Google Scholar 

  105. Wemer J, Wolf H, Apodaca J, zur-Hausen H (1975) Lymphoproliferative disease in a cotton-top marmoset after inoculation with infectious mononucleosis-derived Epstein-Barr virus. Int J Cancer 15: 1000

    PubMed  Google Scholar 

  106. Rogers RP, Ge J-Q, Holley-Guthrie E, et al (1996) Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther 7: 2235

    PubMed  Google Scholar 

  107. Franken M, Estabrooks A, Cavacini L, Sherburne B, Want F, Scadden DT (1996) Epstein-Barr virusdriven gene therapy for EBV-related lymphomas. Nat Med 2:1379

    PubMed  Google Scholar 

  108. Knowles DM, Cesarman E, Chadbum A, et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85: 552

    PubMed  Google Scholar 

  109. Sullivan JLM, Medveczky PM, Forman SJM, Baker SMMT, Monroe JEMS, Mulder C (1984) Epstein-Barr-Virus induced lymphoproliferation. Engl J Med 311: 1163

    Google Scholar 

  110. Sixbey JW, Pagano JS (1985) Epstein-Barr virus transformation of human B lymphocytes despite inhibition of viral polymerase. J Virol 53:299

    PubMed  Google Scholar 

  111. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al (1991) Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J Pathol 165: 289

    PubMed  Google Scholar 

  112. Andersson J (1996) Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis [Suppl] 100: 72

    Google Scholar 

  113. Pagano JS, Datta AK (1982) Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses. Am J Med 73:18–26

    PubMed  Google Scholar 

  114. Field AK, Davies ME, DeWitt C, et al (1983) 9-1[2-Hydroxy-l-(hydroxymethyl)ethoxy]methyllguanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 80: 4139

    PubMed  Google Scholar 

  115. Datta AK, Colby BM, Shaw JE, Pagano JS (1980) Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci USA 77: 5163

    PubMed  Google Scholar 

  116. Lin J-C, Smith MC, Pagano JS (1984) Prolonged inhibitory effect of 9-(1,3-Dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus. J Virol 50: 50

    PubMed  Google Scholar 

  117. Colby BM, Shaw JE, Elion GB, Pagano JS (1980) Effect of acyclovir [9-(2-Hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol 34:560

    PubMed  Google Scholar 

  118. Liu M-Y, Pai C-Y, Shieh S-M, Hsu T-Y, Chen J-Y, Yang C-S (1992) Cloning and expression of a cDNA encoding the Epstein-Barn virus thymidine kinase gene. J Viral Methods 40:107

    Google Scholar 

  119. Colby BM, Shaw JEP, Datta AK, Pagano JS (1982) Replication of Epstein-Barr virus DNA in lymphoblastoid cells treated for extended periods with acyclovir. Am J Med 73:77

    Google Scholar 

  120. Colby BM, Furman PA, Shaw JE, Elion GB, Pagano JS (1981) Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl) guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol 38: 606

    PubMed  Google Scholar 

  121. Pagano JS, Sixbey JW, Lin J-C (1983) Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother 12, [Suppl B]: 113

    PubMed  Google Scholar 

  122. Lin J-C, Nelson DJ, Lambe CU, Choi El (1986) Metabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus. J Virol 60:569

    PubMed  Google Scholar 

  123. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB (1989) Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 43: 67

    PubMed  Google Scholar 

  124. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al (1982) Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N Engl J Med 306:913

    PubMed  Google Scholar 

  125. Gratama JW, Lennette ET, Lonnqvist B, et al (1992) Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J Med Viral 37: 39

    Google Scholar 

  126. Lewin N, Aman P, Akerlund B, et al (1990) Epstein-Barr virus-carrying B cells in the blood during acute infectious mononucleosis give rise to lymphoblastoid lines in vitro by release of transforming virus and by proliferation. Immunol Lett 26:59

    PubMed  Google Scholar 

  127. Ambinder RF, Robertson KD, Moore SM, Yang J (1996) Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Sem Cancer Biol 7:217

    Google Scholar 

  128. Sixbey J, Harmon H, Pagano J (1982) Epstein-Ban virus transformation of human lymphocytes in the presence of acyclovir [9-(2-hydroxethoxymethyl)guanine]. Clin Res 30:521A

    Google Scholar 

  129. Summers WC, Klein G (1976) Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol 18: 151

    PubMed  Google Scholar 

  130. Pagano JS (1979) The Epstein-Barr virus plasmid In: Cummings DJ, et al (eds) Extrachromosomal DNA. Academic Press, New York, pp 235–248

    Google Scholar 

  131. Tosato G, Pike SE, Koski IR, Blaese RM (1982) Selective inhibition of immunoregulatory cell functions by cyclosporin A. J Immunol 128:1986

    PubMed  Google Scholar 

  132. Svedmyr E, Ernberg I, Seeley J, et al (1984) Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clin Immunol Immunopathol 30:437

    PubMed  Google Scholar 

  133. Rickinson AB, Wallace LE, Epstein MA (1980) HLA-restricted T-cell recognition of Epstein-Ban virus-infected B cells. Nature 283: 865

    PubMed  Google Scholar 

  134. Rickinson AB, Moss DJ, Wallace LE, et al (1981) Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res 41:4216

    PubMed  Google Scholar 

  135. Okano M, Thiele GM, Kobayashi RH, et al (1989) Interferon-gamma in a family with x-linked lymphoproliferative syndrome with acute Epstein-Ban virus infection. J Clin Immunol 9:48

    PubMed  Google Scholar 

  136. Purtilo DT (1986) Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients. AIDS Res 2 [Suppl 1]: S177

    PubMed  Google Scholar 

  137. Tosato G, Gerrard TL, Goldman NG, Pike SE (1988) Stimulation of EBV-activated human B cells by monocytes and monocyte products. J Immunol 140:4329

    PubMed  Google Scholar 

  138. Trigg ME, Finlay JL, Sondel PM (1985) Prophylactic acyclovir in patients receiving bone marrow transplants. Engl J Med 312: 1708

    Google Scholar 

  139. Ham JM, Bunchman TE, Campbell DAJ, et al (1994) Cytomegalovirus and Epstein-Barr virus-acquired immunity after sandoglobulin prophylaxis in the pediatric renal transplant population. Transplant Proc 26:20

    Google Scholar 

  140. Hickey D, Nalesnik M, Vivas C, et al (1990) Renal retransplantation in patients who lost their allografts during management of previous post-transplant lymphoproliferative disease. Clin Transplant 4: 187

    Google Scholar 

  141. Darenkov I, Marcarelli MA, Basadonna GP, Friedman ML, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lather MI (1997) Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64: 848

    PubMed  Google Scholar 

  142. Haque T, Thomas JA, Falk KI, et al (1996) Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 77: 1169

    PubMed  Google Scholar 

  143. Khawand N, Light JA, Brems W, Aquino A, Ali A (1989) Does intravenous immunoglobulin prevent primary cytomegalovirus disease in kidney transplant recipients? Transplant Proc 21: 2072

    PubMed  Google Scholar 

  144. Stratta RJ, Shaefer MS, Cushing KA, et al (1992) A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 127:55

    PubMed  Google Scholar 

  145. Gane E, Saliba F, Valdecasas G, et al (1997) Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients. Lancet 350: 1729–1733

    PubMed  Google Scholar 

  146. Winston D, Wirin D, Shaked A, Busuttil RW (1995) Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346: 69

    PubMed  Google Scholar 

  147. Brennan DC, Garlock KA, Singer GG, et al (1997) Prophylactic oral ganciclovir compared to deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64: 1843–1846

    PubMed  Google Scholar 

  148. Badley A, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBemardi M, Zetterman R, Steers JL, Paya C (1997) Prophylaxis of cytometalovirus infection in liver transplantation. Transplantation 64: 66

    PubMed  Google Scholar 

  149. Alrabiah FA, Sacks SL (1996) New antiherpesvirus agents. Drugs 52: 17

    PubMed  Google Scholar 

  150. Squifflet J-P, Mendez R, Neumayer H-H, Lowance D, Coggon G, Lee I (1997) Valaciclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive renal allograft recipients. In: Abstracts of ASTP — 16th Annual Meeting, May 10–14. Scientific Session and Business Meeting Chicago, abst. no. 87

  151. Boyd MR, Satrin S, Kern ER (1993) Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 4 [Suppl 1]: 3

    Google Scholar 

  152. Gnann JW Jr (1994) New antivirals with activity against varicella-zoster virus. Ann Neurol 34 [Suppl 35]1994:S69

    Google Scholar 

  153. Lin J-C, Clercq ED, Pagano JS (1991) Inhibitory effects of acyclic nucleoside phosphonate analogs, including (s)-1-(3-hydroxy-2phosphonylmethoxypropyl) cytosine, on Epstein-Barr virus replication. Antimicrob Agents Chemother: 2440

  154. Lalezari J, Drew W, Glutzer E, et al (1995) (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (Cidofovir): results of a phase 1/11 study of a novel antiviral nucleotide analogue. J Infect Dis 171: 788

    PubMed  Google Scholar 

  155. Lalezari JP, Stagg RJ, Kuppermann BD, et al (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 126: 257

    PubMed  Google Scholar 

  156. Durandy A, Emilie D, Peuchmaur M, et al (1994) Role of IL-6 in promoting growth of human EB V-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 152:5361

    PubMed  Google Scholar 

  157. Tanner J, Tosato G (1991) Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239

    PubMed  Google Scholar 

  158. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JLC (1993) Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 91: 2806

    PubMed  Google Scholar 

  159. Preti HAM, Cabanillas FM, Talpaz MM, Tucker SLP, Seymour JFM, Kurzrock RM (1997) Prognostic value of serum Interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127: 186

    PubMed  Google Scholar 

  160. Gamier J-L, Berger F, Martin X, et al (1995) Post-transplant B-cell lymphomas-correlation of late stage B-cell differentiation and progression of disease; treatment with chimeric monoclonal antibody. Transplant Proc 27: 1777

    PubMed  Google Scholar 

  161. Tosato G, Tanner J, Jones KD, Revel M, Pike SE (1990) Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 64: 3033

    PubMed  Google Scholar 

  162. Jones K, Rivera C, Sgadari C, et al (1995) Infection of human endothelial cells with Epstein-Barr virus. J Exp Med 182:1213

    PubMed  Google Scholar 

  163. Faro A, Kurland G, Michaels MG, et al (1996) Interferon-alpha affects the immune response in posttransplant lymphoproliferative disorder. Am J Respir Crit Care Med 153:1442

    PubMed  Google Scholar 

  164. Kovarik J, Mayer G, Pohanka E, et al (1988) Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 45:402

    PubMed  Google Scholar 

  165. Kramer P, Bijnen AB, Ten Kante FWJ, Jeekel J, Weimar W (1984) Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet I: 989

    Google Scholar 

  166. Yao G-Q, Grill S, Egan W, Cheng Y-C (1993) Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification. Antimicrob Agents Chemother 37: 1420

    PubMed  Google Scholar 

  167. Gutierrez MI, Judde J-G, Magrath IT, Bhatia KG (1996) Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 56: 969

    PubMed  Google Scholar 

  168. Moss DJ, Schmidt C, Elliott S, Suhrbler A, Burrows S, Khanna R (1996) Strategies involved in developing an effective vaccine for EBV-associated diseases. Cancer Res 69: 213

    Google Scholar 

  169. Kuzushima K, Yamamoto M, Kimura H, et al (1996) Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLAmatched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103:192

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Transplantation Services, University of Washington Medical Center, 1959 NE Pacific Street, Box 356174, 98195-6174, Seattle, WA, USA

    C. L. Davis

Authors
  1. C. L. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, C.L. The antiviral prophylaxis of post-transplant lymphoproliferative disorder. Springer Semin Immunopathol 20, 437–453 (1998). https://doi.org/10.1007/BF00838054

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00838054

Keywords

Search

Navigation